Zhiwei Hu

ORCID: 0000-0002-0023-1170 · 17 papers in corpus
other 2026
Journal of molecular medicine (Berlin, Germany) ·doi:10.1007/s00109-026-02710-9

Endometriosis is a chronic, systemic gynecological disorder that affects 190 million women worldwide. Current treatments consist of hormonal suppression and surgical excision; however, both have considerable side effects and a high risk of …

lab-animal 2022
·doi:10.2139/ssrn.4191376

Background: Coronavirus disease 2019 (COVID-19) treatments are still urgently needed for critically and severely ill patients. Human umbilical cord-mesenchymal stem cells (hUC-MSCs) infusion has therapeutic benefits in COVID-19 patients; ho…

other 2020
Reproductive biology ·doi:10.1016/j.repbio.2020.08.005
review 2020
Molecules (Basel, Switzerland) ·doi:10.3390/molecules25214964

Photodynamic diagnosis (PDD) and therapy (PDT) are emerging, non/minimally invasive techniques for cancer diagnosis and treatment. Both techniques require a photosensitizer and light to visualize or destroy cancer cells. However, a limitati…

lab-animal 2020
Scientific reports ·doi:10.1038/s41598-020-59736-3

Triple-negative breast cancer (TNBC), representing ~15% of globally diagnosed breast cancer, is typically an incurable malignancy due to the lack of targetable surface targets for development of effective therapy. To address the unmet need …

other 2018
Reproductive biology ·doi:10.1016/j.repbio.2018.01.009

Endometriosis is a common condition in reproductive-aged women characterized by ectopic endometrial lesions of varied appearance, including red, white, blue, black or powder burn coloration, which contribute to chronic pain and infertility.…

lab-animal 2018
Cancer immunology research ·doi:10.1158/2326-6066.cir-17-0343

Triple-negative breast cancer (TNBC) is a leading cause of breast cancer death and is often associated with BRCA1 and BRCA2 mutation. Due to the lack of validated target molecules, no targeted therapy for TNBC is approved. Tissue factor (TF…

review 2018
Antibodies (Basel, Switzerland) ·doi:10.3390/antib7010008

Accumulating evidence suggests that tissue factor (TF) is selectively expressed in pathological angiogenesis-dependent as well as macrophage-associated human diseases. Pathological angiogenesis, the formation of neovasculature, is involved …

review 2017
Pharmacology & therapeutics ·doi:10.1016/j.pharmthera.2016.10.018

Dichloroacetate (DCA) has several therapeutic applications based on its pharmacological property of inhibiting pyruvate dehydrogenase kinase. DCA has been used to treat inherited mitochondrial disorders that result in lactic acidosis, as we…

lab-animal 2017
Angiogenesis ·doi:10.1007/s10456-016-9530-9

Identification of target molecules specific for angiogenic vascular endothelial cells (VEC), the inner layer of pathological neovasculature, is critical for discovery and development of neovascular-targeting therapy for angiogenesis-depende…

review 2015
Carcinogenesis ·doi:10.1093/carcin/bgv039

Lifestyle factors are responsible for a considerable portion of cancer incidence worldwide, but credible estimates from the World Health Organization and the International Agency for Research on Cancer (IARC) suggest that the fraction of ca…

lab-animal 2011
British journal of cancer ·doi:10.1038/bjc.2011.88

BACKGROUND: The purpose of this study was to test a novel, dual tumour vascular endothelial cell (VEC)- and tumour cell-targeting factor VII-targeted Sn(IV) chlorin e6 photodynamic therapy (fVII-tPDT) by targeting a receptor tissue factor (…

lab-animal 2011
Breast Cancer Research and Treatment ·doi:10.1007/s10549-010-0957-1

The cell surface receptor tissue factor (TF) is regarded as a common but specific target on angiogenic tumor vascular endothelial cells (VECs) and tumor cells in many types of cancer including breast cancer. The purpose of this study is to …

lab-animal 2010
British journal of cancer ·doi:10.1038/sj.bjc.6605760

BACKGROUND: Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two hum…

lab-animal 2010
BMC immunology ·doi:10.1186/1471-2172-11-49

BACKGROUND: Icon is a novel, dual neovascular- and cancer cell-targeting immunotherapeutic agent and has shown efficacy in the treatment of cancer, wet form macular degeneration and endometriosis. However, its underlying mechanism remains t…

lab-animal 2010
BMC cancer ·doi:10.1186/1471-2407-10-235

BACKGROUND: The objective of this study was to develop a ligand-targeted photodynamic therapy (tPDT) by conjugating factor VII (fVII) protein with photosensitiser verteporfin in order to overcome the poor selectivity and enhance the effect …

lab-animal 2010
The American Journal of Pathology ·doi:10.2353/ajpath.2010.090757

Endometriosis is a major cause of chronic pain, infertility, medical and surgical interventions, and health care expenditures. Tissue factor (TF), the primary initiator of coagulation and a modulator of angiogenesis, is not normally express…